Oxford, United Kingdom

Christopher W Redman

This inventor holds 4 USPTO granted patents. Top assignees: Monsanto Company, Isis Innovation Limited. Active years: 1992-1997.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1992-1997

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Christopher W Redman: Innovator in Immunosuppressive Agents

Introduction

Christopher W Redman is a notable inventor based in Oxford, GB. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 4 patents to his name, Redman has established himself as a key figure in the development of novel immunosuppressive agents.

Latest Patents

One of Redman's latest patents focuses on cytotrophoblast antigen and monoclonal antibodies that specifically target immunosuppressive agents. The disclosure describes the isolation of novel immunosuppressive agents from syncytiotrophoblast microvilli membranes. This process involves preparing a minutely subdivided and solubilized preparation of these membranes and isolating the unreduced N-linked oligosaccharides from an extract of the preparation.

Career Highlights

Throughout his career, Christopher W Redman has worked with prominent companies such as Monsanto Company and Isis Innovation Limited. His work in these organizations has contributed to advancements in biotechnology and immunology.

Collaborations

Redman has collaborated with esteemed colleagues, including Peter D Arkwright and Raymond A Dwek. These partnerships have further enhanced his research and innovation in the field.

Conclusion

Christopher W Redman is a distinguished inventor whose work in immunosuppressive agents has made a significant impact in the field of immunology. His innovative patents and collaborations reflect his dedication to advancing scientific knowledge and technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…